Stockreport

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced

SIGA Technologies Inc.  (SIGA) 
US:NASDAQ Investor Relations: investor.siga.com/investor-relations
PDF Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrollin [Read more]